Dr. James Crowe, Director of the Vanderbilt Vaccine Center, discusses COVID-19 vaccine efficacy against the Delta variant, T cell specificity in melanoma, overcoming PD-1 blockade resistance in lung cancer, and advancements in antibodies for viral pathogens. He also explores transitioning from academia to starting a biotech company and the importance of good manufacturing practices in biotech.